NCT07444203Recruiting
Transformative Research in Diabetic Nephropathy 2.0
Transformative Research in Diabetic Nephropathy 2.0: A Proof of Principle Study of SGLT2 Inhibitors (TRIDENT 2.0)
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care. The main questions this study aims to answer are: * Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them? * Are these kidney tissue patterns linked with how kidney health changes over time? Researchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines. Participants will: Let researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 24 Feb 2026
- Start date
- 12 Nov 2025
- Primary completion date
- 30 May 2027
- Lead sponsor
- University of Pennsylvania
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT07444203
What you commit to
- Study type: Observational
- Planned participants: 200
- From 12 Nov 2025 to the primary completion date, 30 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Archived biopsy or surgical tissue unavailable for slide preparation.
Other
- Inability to provide informed consent.
- Any local institutional policy that prohibits release of H\&E slides for research.
Who the study is looking for
- Age ≥18 years
- eGFR ≥10 ml/min/1.73 m2 based on the 2021 race-free CKD-EPI equation13
- Underwent a clinically indicated kidney biopsy, living donor biopsy, or nephrectomy (non-tumor adjacent tissue available).
- Able and willing to provide informed consent for release of one pathology and clinical data abstraction.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Penn Presbyterian Medical Center Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.